Almonertinib Mesilate Drug Asset Due Diligence Report 2026

This Almonertinib Mesilate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

112

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Almonertinib Mesilate can convert its Small molecule drug profile and EGFR L858R x EGFR T790M x EGFR-Ex19del biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Almonertinib Mesilate (query alias: Almonertinib Mesilate)
Modality / target	Small molecule drug; EGFR L858R x EGFR T790M x EGFR-Ex19del; EGFR T790M inhibitors, EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors
Highest global status	Approved
Originator	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Active developers	Hansoh Pharma International Limited, EQRx International, Inc., SFL Pharmaceuticals Deutschland GmbH

The MCP disease footprint includes Advanced Lung Non-Small Cell Carcinoma, EGFR-mutated non-small Cell Lung Cancer, EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600121540	Phase 2	Not yet recruiting	62	Progression-free survival
NCT07624487	Phase 2	Recruiting	50	Molecular response
ChiCTR2600128212	Phase 2	Not yet recruiting	20	Objective response rate, ORR

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Almonertinib Mesilate addresses Advanced Lung Non-Small Cell Carcinoma, EGFR-mutated non-small Cell Lung Cancer, EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-12-17	Glenmark enters collaboration and distribution agreement with Jiangsu Hansoh Pharma for Aumolertinib, a third-generation GFR-TKI to treat NSCLC	Approved	US$1,000.0M stated total
2023-08-04	江苏豪森药业集团有限公司重获阿美替尼在中国境外的研究、开发、生产和商业化权益	Approved	US$100.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO